Skip to main content

Table 3 Univariate and multivariate overall survival analyses

From: The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

Characteristic Hazard ratio (95% CI) P- value
EGFR positive vs EGFR negative 0.91 (0.66 to 1.16) .464
Age >65 vs ≤65 1.04 (0.80 to 1.29) .747
ECOG performance status 2–3 vs 0-1 2.13 (1.66 to 2.60) .002
Therapy with 2- drug vs 3- drug combination 0.82 (0.58 to 1.07) .117
gastroesophageal junction vs Stomach 0.69 (0.40 to 0.97) .009
recurrent disease vs Stage IV at diagnosis 0.84 (0.50 to 1.18) .326
Male vs female 0.92 (0.67 to 1.17) .512
Liver metastasis, yes vs no 1.19 (0.95 to 1.44) .163
Peritoneal metastasis, yes vs no 1.26 (1.00 to 1.52) .079
Intestinal vs diffuse/mixed 0.90 (0.63 to 1.16) .43
Multivariate Overall Survival Analysis   
Characteristic Hazard ratio (95% CI) P- value
EGFR positive vs EGFR negative 0.85 (0.57 to 1.13) .247
Age >65 vs ≤65 1.16 (0.88 to 1.45) .299
Therapy with 2- drug vs 3- drug combination 0.71 (0.39 to 0.97) .033
gastroesophageal junction vs Stomach 0.78 (0.43 to 1.14) .176
recurrent disease vs Stage IV at diagnosis 0.71 (0.33 to 1.10) .087
Male vs female 1.01 (0.71 to 1.30) .959
Intestinal vs. diffuse/mixed 0.9 (0.59 to 1.22) .517
  1. a Univariate Overall Survival Analysis.